GlaxoSmithKline’s unit ViiV Healthcare said the company’s two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2020-03-09 11:21:462020-03-09 12:45:11GSK’s HIV combo treatment meets main goal in late-stage study
